BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38460250)

  • 1. Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population.
    Lu Q; Wang N; Jiang K; Zhou H; Zhang P; Zhang J; Wang S; Sun P; Xu F
    ESMO Open; 2024 Mar; 9(3):102389. PubMed ID: 38460250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population.
    Wang L; Zhai Q; Lu Q; Lee K; Zheng Q; Hong R; Wang S
    Ann Med; 2021 Dec; 53(1):1358-1369. PubMed ID: 34396843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
    Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
    Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases.
    Huang RSP; Haberberger J; McGregor K; Mata DA; Decker B; Hiemenz MC; Lechpammer M; Danziger N; Schiavone K; Creeden J; Graf RP; Strowd R; Lesser GJ; Razis ED; Bartsch R; Giannoudis A; Bhogal T; Lin NU; Pusztai L; Ross JS; Palmieri C; Ramkissoon SH
    Oncologist; 2021 Oct; 26(10):835-844. PubMed ID: 34105210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
    Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
    Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordance of PIK3CA and TP53 mutations between breast cancer brain metastases and matched primary tumors.
    Thulin A; Andersson C; Werner Rönnerman E; De Lara S; Chamalidou C; Schoenfeld A; Kovács A; Fagman H; Enlund F; Linderholm BK
    Sci Rep; 2021 Dec; 11(1):23548. PubMed ID: 34876602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival.
    Giannoudis A; Sartori A; Eastoe L; Zakaria R; Charlton C; Hickson N; Platt-Higgins A; Rudland PS; Irwin D; Jenkinson MD; Palmieri C
    Breast Cancer Res Treat; 2021 Nov; 190(2):241-253. PubMed ID: 34499316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer.
    Lee JY; Park K; Lim SH; Kim HS; Yoo KH; Jung KS; Song HN; Hong M; Do IG; Ahn T; Lee SK; Bae SY; Kim SW; Lee JE; Nam SJ; Kim DH; Jung HH; Kim JY; Ahn JS; Im YH; Park YH
    Oncotarget; 2015 Dec; 6(41):43731-42. PubMed ID: 26527317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic alterations and their association with clinicopathologic characteristics in advanced breast carcinomas: focusing on clinically actionable genetic alterations.
    Freitag CE; Mei P; Wei L; Parwani AV; Li Z
    Hum Pathol; 2020 Aug; 102():94-103. PubMed ID: 32445652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.
    Saunus JM; Quinn MC; Patch AM; Pearson JV; Bailey PJ; Nones K; McCart Reed AE; Miller D; Wilson PJ; Al-Ejeh F; Mariasegaram M; Lau Q; Withers T; Jeffree RL; Reid LE; Da Silva L; Matsika A; Niland CM; Cummings MC; Bruxner TJ; Christ AN; Harliwong I; Idrisoglu S; Manning S; Nourse C; Nourbakhsh E; Wani S; Anderson MJ; Fink JL; Holmes O; Kazakoff S; Leonard C; Newell F; Taylor D; Waddell N; Wood S; Xu Q; Kassahn KS; Narayanan V; Taib NA; Teo SH; Chow YP; kConFab ; Jat PS; Brandner S; Flanagan AM; Khanna KK; Chenevix-Trench G; Grimmond SM; Simpson PT; Waddell N; Lakhani SR
    J Pathol; 2015 Nov; 237(3):363-78. PubMed ID: 26172396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas.
    Sun X; Zuo K; Yao Q; Zhou S; Shui R; Xu X; Bi R; Yu B; Cheng Y; Tu X; Lu H; Yang W
    Mod Pathol; 2020 Dec; 33(12):2473-2482. PubMed ID: 32504034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
    van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
    Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance of genomic alterations between primary and recurrent breast cancer.
    Meric-Bernstam F; Frampton GM; Ferrer-Lozano J; Yelensky R; Pérez-Fidalgo JA; Wang Y; Palmer GA; Ross JS; Miller VA; Su X; Eroles P; Barrera JA; Burgues O; Lluch AM; Zheng X; Sahin A; Stephens PJ; Mills GB; Cronin MT; Gonzalez-Angulo AM
    Mol Cancer Ther; 2014 May; 13(5):1382-9. PubMed ID: 24608573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive molecular biomarker identification in breast cancer brain metastases.
    Schulten HJ; Bangash M; Karim S; Dallol A; Hussein D; Merdad A; Al-Thoubaity FK; Al-Maghrabi J; Jamal A; Al-Ghamdi F; Choudhry H; Baeesa SS; Chaudhary AG; Al-Qahtani MH
    J Transl Med; 2017 Dec; 15(1):269. PubMed ID: 29287594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.
    Takeda M; Takahama T; Sakai K; Shimizu S; Watanabe S; Kawakami H; Tanaka K; Sato C; Hayashi H; Nonagase Y; Yonesaka K; Takegawa N; Okuno T; Yoshida T; Fumita S; Suzuki S; Haratani K; Saigoh K; Ito A; Mitsudomi T; Handa H; Fukuoka K; Nakagawa K; Nishio K
    Oncologist; 2021 Apr; 26(4):e588-e596. PubMed ID: 33325566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genes associated with increased brain metastasis risk in non-small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036).
    Wang H; Ou Q; Li D; Qin T; Bao H; Hou X; Wang K; Wang F; Deng Q; Liang J; Zheng W; Wu X; Wang X; Shao YW; Mou Y; Chen L
    Cancer; 2019 Oct; 125(20):3535-3544. PubMed ID: 31287555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.
    Priedigkeit N; Hartmaier RJ; Chen Y; Vareslija D; Basudan A; Watters RJ; Thomas R; Leone JP; Lucas PC; Bhargava R; Hamilton RL; Chmielecki J; Puhalla SL; Davidson NE; Oesterreich S; Brufsky AM; Young L; Lee AV
    JAMA Oncol; 2017 May; 3(5):666-671. PubMed ID: 27926948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
    Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
    Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalent landscape of tumor genomic alterations of luminal B1 breast cancers using a comprehensive genomic profiling assay in Taiwan.
    Chen BF; Tsai YF; Lien PJ; Lin YS; Feng CJ; Chen YJ; Cheng HF; Liu CY; Chao TC; Lai JI; Tseng LM; Huang CC
    Breast Cancer; 2024 Mar; 31(2):217-227. PubMed ID: 38070067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
    Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
    J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.